

The Commonwealth of Massachusetts Executive Office of Health and Human Services One Ashburton Place, Room 1109 Boston, Massachusetts 02108

Tel: (617) 573-1600 Fax: (617) 573-1891 www.mass.gov/eohhs

CHARLES D. BAKER Governor

KARYN E. POLITO Lieutenant Governor

MARYLOU SUDDERS Secretary

Administrative Bulletin 19-06

101 CMR 320.00 Clinical Laboratory Services

Effective January 1, 2019

Procedure Code Update

Pursuant to 101 CMR 320.01(3), the Executive Office of Health and Human Services is adding new procedure codes and deleting outdated codes for clinical laboratory services. As set forth in 101 CMR 320.01(3)(c), the rates for code additions are priced at 74.67% of the prevailing Medicare fee if available. The changes, effective January 1, 2019, are as follows.

Code	Change	Rate	Code Description (if applicable)
81163	Addition	\$349.46	BRCA1 (BRCA1, DNA repair associated), BRCA2 (BCA2,
			DNA repair associated) (eg, hereditary breast and ovarian cancer)
			gene analysis; full sequence analysis
81164	Addition	\$436.24	BRCA1 (BRCA1, DNA repair associated), BRCA2 (BCA2,
			DNA repair associated) (eg, hereditary breast and ovarian cancer)
			gene analysis; full duplication /deletion analysis (ie, detection of
			large gene rearrangement)
81165	Addition	\$211.23	BRCA1 (BRCA1, DNA repair associated) (eg, hereditary breast
			and ovarian cancer) gene analysis; full sequence analysis
81166	Addition	\$225.02	BRCA1 (BRCA1, DNA repair associated) (eg, hereditary breast
			and ovarian cancer) gene analysis; full duplication/deletion
			analysis (ie, detection of large gene rearrangements)
81167	Addition	\$211.23	BRCA2 (BRCA2, DNA repair associated) (eg, hereditary breast
			and ovarian cancer) gene analysis; full duplication/deletion
			analysis (ie, detection of large rearrangements)
81171	Addition	\$102.30	AFF2 (AF4/FMR2 family, member 2 [FMR2] (eg, fragile X
			mental retardation 2 [FRAXE]) gene analysis; evaluation to



Code	Change	Rate	Code Description (if applicable)
			detect abnormal (eg, expanded) alleles
81172	Addition	\$205.22	AFF2 (AF4/FMR2 family, member 2 [FMR2] (eg, fragile X
			mental retardation 2 [FRAXE]) gene analysis; characterization of
			alleles (eg, expanded size and methylation status)
81173	Addition	\$225.02	AR (androgen receptor) (eg, spinal and bulbar muscular atrophy,
			Kennedy disease, X chromosome inactivation) gene analysis; full
			gene sequence
81174	Addition	\$138.29	AR (androgen receptor) (eg, spinal and bulbar muscular atrophy,
			Kennedy disease, X chromosome inactivation) gene analysis;
			known familial variant
81177	Addition	\$102.30	ATN1 (atrophin 1) (eg, dentatorural-pallidoluysian atrophy) gene
			analysis; evaluation to detect abnormal (eg, expanded) alleles
81178	Addition	\$102.30	ATXN1 (ataxin 1) (eg, spinocerebellar ataxia) gene analysis;
			evaluation to detect abnormal (eg, expanded) alleles
81179	Addition	\$102.30	ATXN2 (ataxin 2) (eg, spinocerebellar ataxia) gene analysis;
			evaluation to detect abnormal (eg, expanded) alleles
81180	Addition	\$102.30	ATXN3 (ataxin 3) (eg, spinocerebellar ataxia, Machado-Joseph
			disease) gene analysis, evaluation to detect abnormal (eg,
			expanded) alleles
81181	Addition	\$102.30	ATXN7 (ataxin 7) (eg, spinocerebellar ataxia) gene analysis,
			evaluation to detect abnormal (eg, expanded) alleles
81182	Addition	\$102.30	ATXN8OS (ATXN8 opposite strand [non-protein coding]) (eg,
			spinocerebellar ataxia) gene analysis, evaluation to detect
			abnormal (eg, expanded) alleles
81183	Addition	\$102.30	ATXN10 (ataxin 10) (eg, spinocerebellar ataxia) gene analysis;
			evaluation to detect abnormal (eg, expanded) alleles
81184	Addition	\$102.30	CACNA1A (calcium voltage-gated channel subunit alpha1 A)
			(eg, spinocerebellar ataxia) gene analysis; evaluation to detect
			abnormal (eg, expanded) alleles
81185	Addition	\$631.91	CACNA1A (calcium voltage-gated channel subunit alpha1 A)
			(eg, spinocerebellar ataxia) gene analysis; full gene sequence
81186	Addition	\$138.29	CACNA1A (calcium voltage-gated channel subunit alpha1 A)
<u> </u>			(eg, spinocerebellar ataxia) gene analysis; known familial variant
81187	Addition	\$102.30	CNBP (CCHC-type zinc finger nucleic acid binding protein) (eg,
			myotonic dystrophy type 2) gene analysis, evaluation to detect
			abnormal (eg, expanded) alleles
81188	Addition	\$102.30	CSTB (cystatin B) (eg, Unverricht-Lundborg disease) gene
			analysis; evaluation to detect abnormal (eg, expanded) alleles
81189	Addition	\$205.22	CSTB (cystatin B) (eg, Unverricht-Lundborg disease) gene
			analysis; full gene sequence
81190	Addition	\$138.29	CSTB (cystatin B) (eg, Unverricht-Lundborg disease) gene
			analysis; known familial variant
81204	Addition	\$102.30	AR (androgen receptor) (eg, spinal and bulbar muscular atrophy,
			Kennedy disease, X chromosome inactivation) gene analysis;
			characterization of alleles (eg, expanded size of methylation
			status)
81211	Discontinued		
81213	Discontinued		
81214	Discontinued		

Code	Change	Rate	Code Description (if applicable)
81233	Addition	\$130.97	BTK (Bruton's tyrosine kinase) (eg, chonic lymphocytic
			leukemia) gene analysis, common variants (eg, C481S, C481R,
			C481F)
81234	Addition	\$102.30	DMPK (DM1 protein kinase) (eg, myotonic dystrophy type 1)
			gene analysis; evaluation to detect abnormal (expanded) alleles
81236	Addition	\$211.23	EZH2 (enhancer of zeste 2 polycomb repressive complex 2
			subunit) (eg, diffuse large B-cell lymphoma) gene analysis,
			common variant(s) (eg, codon 646)
81237	Addition	\$130.97	EZH2 (enhancer of zeste 2 polycomb repressive complex 2
			subunit) (eg, myelodysplastic syndrome, myeloproliferative
01000		+	neoplasms) gene analysis;
81239	Addition	\$205.22	DMPK (DM1 protein kinase) (eg, myotonic dystrophy type 1)
212=1		+10000	gene analysis; characterization of alleles (eg, expanded size)
81271	Addition	\$102.30	HTT (huntingtin) (eg., Huntington disease) gene analysis;
0.1.5		+	evaluation to detect abnormal (eg, expanded) alleles
81274	Addition	\$205.22	HTT (huntingtin) (eg., Huntington disease) gene analysis;
01201		4104 40	characterization of alleles (eg, expanded) alleles
81284	Addition	\$102.30	FXN (frataxin) (eg, Friedreich ataxia) gene analysis; evaluation
01205	A 1.1''	Φ205.22	to detect abnormal (expanded) alleles
81285	Addition	\$205.22	FXN (frataxin) (eg, Friedreich ataxia) gene analysis;
01206	A 1.1''	Φ205.22	characterization of alleles (eg, expanded size)
81286	Addition	\$205.22	FXN (frataxin) (eg, Friedreich ataxia) gene analysis; full gene
01200	A 11141	¢120.20	sequence
81289	Addition	\$138.29	FXN (frataxin) (eg, Friedreich ataxia) gene analysis; known
81305	Addition	\$130.97	familial variant(s) MYD88 (myeloid differentiation primary response 88) (eg,
01303	Addition	\$130.97	Waldenstrom's macroglobulinemia), lymphoplasmacytic
			leukemia) gene analysis, p.Leu265Pro (L265P) variant
81306	Addition	\$217.56	NUTD15 (nudix hydrolase 15) (eg, drug metabolism) gene
01300	Tradition	Ψ217.30	analysis; common variant(s) (eg, *2, *3, *4, *5, *6)
81312	Addition	\$102.30	PABPN1 (poly [A] binding proteinnuclear 1) (eg,
		Ψ102.20	oculopharyngeal muscular dystrophy) gene analysis, evaluation
			to detect abnormal (eg, expanded) alleles
81320	Addition	\$217.56	PLCG2 (phospholipase C gamma 2) (eg, chronic lymphocytic
		, , , , , , ,	leukemia) gene analysis, common variants (eg, R665W, S707F,
			L845F)
81320	Addition	\$217.56	PLCG2 (phospholipase C gamma 2) (eg, chronic lymphocytic
			leukemia) gene analysis, common variants (eg, R665W, S707F,
			L845F)
81329	Addition	\$102.30	SMN1 (survival of motor neon 1, telemetric) (eg, spinal
			muscular atrophy) gene analysis; dosage/deletion analysis (eg,
			carrier testing), includes SMN2 (survival of motor neuron 2,
			centromeric) analysis, if performed
81333	Addition	\$102.30	TGFBI (transforming growth factor beta-induced) (eg, corneal
			dystrophy) gene analysis, common variants (eg, R124H, R124C,
0100			R124L, R555W, R555Q)
81336	Addition	\$225.02	SMN1 (survival of motor neon 1, telemetric) (eg, spinal muscular
01007	A 1.11.1	44.00.20	atrophy) gene analysis; full gene analysis
81337	Addition	\$138.29	SMN1 (survival of motor neon 1, telemetric) (eg, spinal muscular

Code	Change	Rate	Code Description (if applicable)
			atrophy) gene analysis; known familial variant(s)
81343	Addition	\$102.30	PPP2R2B (protein phosphatase 2 regulatory subunit Bbeta) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) alleles
81344	Addition	\$102.30	TBP (TATA box binding protein) (spinoceenellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) alleles
81345	Addition	\$138.29	TERT (telomerase reverse transcriptase) (eg, thyroid carcinoma, glioblastoma multiforme) gene analysis, targeted sequence analysis (eg, promoter region)
81443	Addition	\$1828.34	Genetic testing for severe inherited conditions (eg, cystic fibrosis, Ashkenazi Jewish associated disorders [eg, Bloom syndrome, Canavan disease, Fanconi anemia type C, mucolipidosis yipe VI, Gaucher disease, Tay-Sachs disease], beta humoglobinopathies, phenylketonuria, galactosemia), genomic sequence analysis panel, must include sequencing of at least 15 genes (eg, SCADM, ARSA, ASPA, ATP7B, BCKDHA, BCDHB, BLM, CFTR, DHCR7, FANCC, G6PC, GAA, GALT, GBA, GBE1, HBB, HEXA, IBKAP, MCOLN1, PAH)
81518	Addition	\$2891.97	Oncology (breast), mRNA, gene expression profiling by real-time RT-PCR of 11genes (7 content and 4 housekeeping), utilizing formalin-fixed paraffin-embedded tissue, algorithms reported as percentage risk for metastatic recurrence and likelihood of benefit from extended endocrine therapy
81596	Addition	\$53.90	Infectious disease, chronic hepatitis C virus (HCV) infection, six biochemical assays (ALT, A2- macroglobulin, apolipoprotein A-1, totalo bilirubin, GGT, and haptoglobin) utilizing serum, prognostic algorithm reported as scores for fibrosis and necroinflammatory activity in liver
82642	Addition	\$24.29	Dihydrotestosterone (DHT)
83722	Addition	\$26.18	Lipoprotein, direct measurement; small dense LDL cholesterol